Our Journey Rooted in Innovation
Galileo Research drives progress today and beyond, building on a legacy of scientific excellence. With decades of discovery, collaboration, and innovation, we stand as a trusted partner in non-clinical research, poised to shape the future of life sciences.
With a wide range of expertise in GLP e non GLP-compliant studies across diverse industries, Galileo Research becomes an extension of client’s R&D team to boost research and move products to market more effectively.
Galileo Research was founded as a spin-off of Abiogen Pharma’s R&D Division, cementing its commitment to innovative, high-quality research. This milestone marked the beginning of a new chapter, focused on expanding capabilities in non-clinical studies and regulatory compliance.
Abiogen Pharma was established following Merck & Co.'s acquisition of Istituto Gentili. The Research Centre carried forward its groundbreaking work in bone diseases, oncology, and CNS research, building on its history of drug discovery and development.
The Istituto Gentili Research Centre achieved global recognition by discovering and patenting groundbreaking bisphosphonates, including clodronate, alendronate, and neridronate. These molecules revolutionized treatment approaches for bone diseases and were later licensed to leading pharmaceutical companies like Merck & Co. and Boehringer Mannheim.
The foundation of Istituto Gentili’s Research Centre marked the beginning of its long-standing dedication to scientific innovation, with a focus on addressing unmet medical needs.
A Century of Commitment to Science1935: Istituto Galenico evolved into Istituto Gentili S.p.A., signifying growth and broader ambitions.
1917: Alfredo Gentili laid the groundwork for a future of innovation by founding Istituto Galenico, the precursor to today’s Galileo Research.
